[opensourcepharma] Recent Items Relevant to Open Source Pharma

[Matthew Todd]

Dear all,

A collection of recent items that might be of interest to you all that have
built up in my browsers during the recent grant-writing bonanza in
Australia.

1) Call from the NIH on "Big Data to Knowledge (BD2K) Advancing Biomedical
Science Using Crowdsourcing and Interactive Digital Media"

http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-15-006.html

2) The NIH screen for known drugs showing promise vs Ebola, featuring John
McKew

http://www.nature.com/emi/journal/v3/n12/full/emi201488a.html

3) Whole issue of Chem Rev on neglected disease drug discovery

http://pubs.acs.org/doi/abs/10.1021/cr500546h

4) "The Drugs for Neglected Diseases initiative (DNDi) has been awarded US$
10 million by the United States Agency for International Development
(USAID) to develop new treatments for onchocerciasis (river blindness) and
lymphatic filariasis (elephantiasis) - the first-ever USAID grant for
neglected tropical disease research and development (R&D)."

http://phys.org/wire-news/180182595/dndi-receives-us10-million-from-usaid-to-develop-new-drugs-for-n.html

5) Articles from NRDD in 2014 making claim that pharma R&D productivity is
"on the comeback trail"

http://www.nature.com/nrd/journal/v13/n5/full/nrd4320.html

and that precompetitive research is important

http://www.nature.com/nrd/journal/v13/n2/full/nrd4230.html

and the state of UK academic drug discovery

http://www.nature.com/nrd/journal/v13/n1/full/nrd4200.html

and article on the proposed Human Vaccines Project

http://www.nature.com/nrd/journal/v14/n1/full/nrd4528.html

a feature/retrospective of Bayer's Grants4Targets open innovation scheme

http://www.nature.com/nrd/journal/v14/n1/full/nrd3078-c2.html

and the possible use of "delinkage" strategies in the funding of antibiotic
drug discovery R&D

http://www.nature.com/nrd/journal/v13/n10/full/nrd4455.html

and an interesting recent postmortem on the results of Bayer donating
compounds to external collaborators: "Remarkably, the interactions within
this compound-donation programme had a positive influence on the
recipient's opinion of both pharmaceutical research in general and of Bayer
in particular. "

http://www.nature.com/nrd/journal/vaop/ncurrent/full/nrd4008-c1.html

6) Proposal to extend drug patent lifetimes by a year and reinvest funds in
e.g. the NIH

http://www.nature.com/nrd/journal/v14/n2/full/nrd4454-c1.html

as a counterpoint there was a WashPo article on "Why patents are
innovation's worst enemy"

http://www.washingtonpost.com/blogs/innovations/wp/2015/03/11/heres-why-patents-are-innovations-worst-enemy/

7) Report from the Institute of Medicine on "Sharing Clinical Trial Data:
Maximizing Benefits, Minimizing Risk"

http://www.iom.edu/Reports/2015/Sharing-Clinical-Trial-Data.aspx

8) Thinklab - an initiative that uses project funds to pay for
contributions to open projects, an interesting idea fraught with risks that
is worth exploring (my view)

http://thinklab.com/participate

9) A recent John Oliver piece on the practice of marketing to doctors

https://www.youtube.com/watch?v=YQZ2UeOTO3I


I'm talking at conferences in London in May that have some emphasis on OSP (
AcademiaPharma <http://academiapharma.com/> and ISNTD-d3
<http://www.isntdd3.com/>) - I mention this in case these provide
opportunities to meet up.

Best wishes everyone,

Mat

-- 
MATTHEW TODD | Associate Professor
School of Chemistry | Faculty of Science

THE UNIVERSITY OF SYDNEY
Rm 519, F11 | The University of Sydney | NSW | 2006
T +61 2 9351 2180  | F +61 2 9351 3329  | M +61 415 274104
E matthew.todd at sydney.edu.au | W
http://sydney.edu.au/science/chemistry/research/todd.html | W
http://opensourcemalaria.org/

CRICOS 00026A
This email plus any attachments to it are confidential. Any unauthorised
use is strictly prohibited. If you receive this email in error, please
delete it and any attachments.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.okfn.org/pipermail/opensourcepharma/attachments/20150318/14865f0a/attachment.html>